Scholarlink

Abstract <p>Bladder cancer (BCa) remains a significant clinical challenge because of high recurrence rates and variable response to immunotherapy and chemotherapy. Recent studies have highlighted the role of N6-methyladenosine (m<sup>6</sup>A) modification in RNA in the regulation of various cellular processes, including tumor progression and drug resistance. The review examines the impact of m<sup>6</sup>A methylation on BCa pathogenesis, with a particular special focus on the role of m<sup>6</sup>A pathway factors and m<sup>6</sup>A-modified RNAs in tumorigenesis, proliferation, invasion, and migration of cancer cells. The mechanisms of m<sup>6</sup>A-mediated chemotherapy resistance in BCa cells are discussed, including single nucleotide polymorphisms in m<sup>6</sup>A-associated patterns. Significant advances in the high-throughput analysis of m<sup>6</sup>A methylation have enabled development of novel m<sup>6</sup>A-based biomarkers for the risk assessment, early diagnostics, and prediction of relapse and treatment response in BCa. The review outlines the prospects of the m<sup>6</sup>A-based molecular diagnostics in BCa.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Role of m6A-RNA Methylation in the Development, Progression, and Treatment Response of Bladder Cancer

  • 期刊论文

  • 发表日期：

    2025年6月1日

查看全文
  • Tatiana Sinyagovskaya,
  • Yuliya Li,
  • Natalya Vinchevskaya-Khmelnitskaya,
  • Aisha Agabalaeva,
  • Natalia Ponomareva,
  • Sergey Brezgin,
  • Irina Goptar,
  • Vladimir Chulanov,
  • Alim Dymov,
  • Andrey Vinarov,
  • Dmitry Kostyushev,
  • Anastasiya Kostyusheva

摘要

Abstract

Bladder cancer (BCa) remains a significant clinical challenge because of high recurrence rates and variable response to immunotherapy and chemotherapy. Recent studies have highlighted the role of N6-methyladenosine (m6A) modification in RNA in the regulation of various cellular processes, including tumor progression and drug resistance. The review examines the impact of m6A methylation on BCa pathogenesis, with a particular special focus on the role of m6A pathway factors and m6A-modified RNAs in tumorigenesis, proliferation, invasion, and migration of cancer cells. The mechanisms of m6A-mediated chemotherapy resistance in BCa cells are discussed, including single nucleotide polymorphisms in m6A-associated patterns. Significant advances in the high-throughput analysis of m6A methylation have enabled development of novel m6A-based biomarkers for the risk assessment, early diagnostics, and prediction of relapse and treatment response in BCa. The review outlines the prospects of the m6A-based molecular diagnostics in BCa.